CNS Biomarker Atlas
CNS Biomarker Atlas: blood biomarkers for brain diseases
An interactive guide to the blood biomarkers used in neurodegenerative disease research and CNS clinical trials: which brain cells they come from, which diseases they track, and when measuring them inside brain-derived extracellular vesicles (EVs) adds signal that whole plasma misses.
From brain to blood
Pick a brain cell type to see the biomarkers it releases.

Neurons
The cells that carry signals. Vesicles from neurons report axonal injury, synaptic change, protein pathology and drug-pathway activity.
Astrocytes
Support cells that react early to injury and amyloid. Their markers read out reactive gliosis.
Oligodendrocytes
The myelin-forming cells, and the site of α-synuclein inclusions in multiple system atrophy.
Microglia
The brain’s immune cells, and a window on neuroinflammation.
How a brain signal reaches the blood tube
- 01Brain cells release vesiclesEach carries proteins and RNA from its cell of origin.
- 02Vesicles reach the bloodstreamThere they mix with vesicles from the rest of the body.
- 03500 µL of plasma or serumEDTA plasma or serum from a routine blood draw.
- 04ExoSORT™ isolationProprietary antibodies against neuronal and oligodendroglial surface proteins capture brain-derived vesicles.
- 05The cargo is measuredBiomarkers are read from inside the brain’s own vesicles. How ExoSORT™ works
Disease × biomarker map
Switch between whole plasma and brain-derived EVs to see where reading the brain’s own vesicles adds signal. Hover over a cell to compare both sample types.
| Disease | NfL | GFAP | p-Tau217 | Aβ42/40 | α-synuclein | TDP-43 | UCH-L1 |
|---|---|---|---|---|---|---|---|
| Alzheimer’s disease | |||||||
| Parkinson’s disease | |||||||
| Lewy body dementia | |||||||
| Multiple system atrophy | |||||||
| PSP / CBD | |||||||
| ALS | |||||||
| Frontotemporal dementia | |||||||
| Huntington’s disease | |||||||
| Multiple sclerosis | |||||||
| Traumatic brain injury | |||||||
| Stroke |
Biomarkers in the atlas
Each marker links to a deeper guide: what it measures, which trials use it, and how NeuroDex runs it.
A structural protein of axons released when neurons are damaged. The most widely used marker of neurodegeneration rate across diseases.
An astrocyte protein that rises with reactive gliosis, early in Alzheimer’s disease and after traumatic brain injury.
A phosphorylated form of tau that tracks Alzheimer’s pathology closely in blood.
The ratio of two amyloid-beta forms; a lower ratio reflects amyloid build-up in the brain.
The protein that aggregates in Parkinson’s disease, Lewy body dementia and MSA. Also abundant in blood cells, which is why brain-derived EVs matter.
The protein that mislocalises in most ALS and about half of FTD cases. Expressed throughout the body, so brain-derived EVs help isolate the brain signal.
A neuronal enzyme released after acute brain injury, used together with GFAP in traumatic brain injury.
Signalling proteins measured in brain-derived EVs to show a drug reached its target in the brain.
Biomarker Finder
Which biomarkers fit your trial?
Choose an indication, a phase and what you need to show. Get a suggested starting panel in under a minute.
Frequently asked questions
What is a CNS blood biomarker?
A protein or other molecule measured in blood that reflects what is happening in the brain or spinal cord, such as nerve-cell injury (NfL), astrocyte activation (GFAP) or disease pathology (p-Tau217, α-synuclein, TDP-43).
Why measure biomarkers inside brain-derived extracellular vesicles?
Many CNS proteins, including α-synuclein and TDP-43, are also made outside the brain. Isolating vesicles released by brain cells ties the measurement to the brain instead of to blood cells or other tissues.
Which blood biomarkers are used in Alzheimer’s disease trials?
p-Tau217 and the Aβ42/40 ratio for amyloid and tau pathology, GFAP for astrocyte activation, and NfL for neurodegeneration.
What sample does NeuroDex need?
A minimum of 500 µL of EDTA plasma or serum per timepoint, shipped frozen on dry ice. Results are typically ready 2–3 weeks after the samples arrive, depending on study size.
Next step
Request a sample-feasibility review
Tell us your indication, sample type and volume. Our scientists confirm which markers your samples can support.

